How Scientific Publication Strategy Serves as a Biotech Marketing Engine

Many biotech companies see scientific publications as just another regulatory requirement to complete after a clinical trial. However, the companies making real progress with payers, investors, and physicians view their publication plans as a key part of how they communicate value. Publishing your data in the right peer-reviewed journals, reaching key opinion leaders, and presenting at important medical conferences can achieve marketing results that paid advertising cannot match. This article explains how a thoughtful publication strategy can become your most credible marketing tool.

A strategic approach to scientific publishing offers unique benefits for biotech companies.

A scientific publication strategy means planning ahead about what data to publish, where to publish it, and when. This approach helps connect your clinical and preclinical evidence with the people who need to trust it before they prescribe, reimburse, fund, or partner with your therapy.

There is a big difference between publishing just to meet requirements and publishing with a clear plan. Without a strategy, your data may end up in journals that your target audience never reads. With a strategy, each publication serves a purpose, like encouraging clinical adoption, supporting payer submissions, or attracting Series B funding.

“We see biotech teams spend years generating strong efficacy and safety data, then lose momentum because they don’t have a plan for how that evidence reaches the people making prescribing and reimbursement decisions. The publication strategy is not a post-trial chore. It is part of the commercial plan.” — Strategy Team, Emulent Marketing.

Key goals that a publication strategy serves:

• Clinical credibility: Peer-reviewed publications show physicians and medical affairs teams that your efficacy and safety data have been checked and validated by independent experts before reaching them.
• Payer evidence package: Health technology assessment groups and payers review published health economics and outcomes research (HEOR) data when making coverage decisions.
• Investor confidence: Regularly publishing in respected journals demonstrates to institutional investors that your science is credible and that your pipeline is advancing.
• Regulatory support: Well-documented publications create a public record of clinical evidence that supports FDA submissions and post-market commitments.

With these goals in mind, building credibility with stakeholders requires targeted publication venues. How, then, do peer-reviewed journals help accomplish this?

Peer-reviewed journals do more than just share results. They are the primary way the medical and scientific community gives new therapies credibility. When your research is published in a journal indexed on PubMed or MEDLINE, it becomes part of a searchable record that doctors, pharmacists, and formulary committees use to evaluate treatments.

Choosing the right journal links your publication and marketing strategies. For example, a Phase II trial published in a general oncology journal reaches a different audience than one published in a specialty hematology journal. The key is to make sure the right specialists are reading and citing your work, not just to focus on impact factor. Prioritize audience fit to make your scientific communication more effective.

Citation metrics, which show how often other researchers reference your work, also help build a record of credibility. High citation counts signal to search engines, payers, and clinicians that your evidence is considered important by the wider scientific community.

What to think about when selecting journals for your publication plan:

• Audience alignment: Review the journal’s readership and editorial focus to confirm your target clinicians are actively reading and contributing to it.
• Indexing in PubMed and MEDLINE: These databases are where physicians and researchers search for evidence, making indexing a baseline requirement for broad visibility.
• Open-access options: Open-access publishing removes paywalls and increases the number of clinicians, payers, and partners who can read your full study without institutional access.
• Turnaround time: Some journals take six months or more to review submissions. If you have a product launch or regulatory milestone coming up, timing is just as important as journal prestige.

In addition to choosing journals wisely, collaborating with key opinion leaders (KOLs) strengthens your publication strategy.

Key opinion leaders, commonly called KOLs, are senior physicians and researchers whose work and institutional affiliations carry significant influence with both clinical and payer audiences. When a recognized KOL author or co-author publishes a publication that includes your therapy’s data, the credibility transfer is real. Clinicians who respect that researcher’s track record pay closer attention to the findings.

KOL engagement is not just about getting a name on a paper. It is about building ongoing scientific relationships with people who understand your therapy’s mechanism of action and can independently speak to its clinical value. KOLs who present your data at major medical conferences, serve on advisory boards, and publish independent commentary on your clinical results become part of your scientific communications network.

“Biotech companies sometimes treat KOL engagement as a one-time ask before a conference presentation. The teams that do it well treat it as a years-long relationship built on scientific exchange, not just a media placement. That difference shows up clearly in how physicians respond to the data.” — Strategy Team, Emulent Marketing.

How to build KOL relationships that strengthen your publication strategy:

• Early engagement during clinical development: Involving KOLs in study design and endpoint selection, not just publication authorship, creates genuine scientific investment in the research outcomes.
• Advisory boards with real input: Advisory boards that offer KOLs substantive influence over research direction generate more authentic scientific advocacy than those structured purely as feedback sessions.
• Supporting independent research: When KOLs pursue investigator-initiated studies using your therapy, the resulting publications carry a level of independence that company-sponsored studies cannot replicate.
• Congress abstracts and podium presentations: Supporting KOLs who submit abstracts to major congresses like ASCO, ASH, or AACR expands your data’s reach beyond the journal readership.

Conference presentations further expand your data’s impact, particularly when integrated with your overall publication strategy.

Major medical and scientific conferences spread published evidence to wider audiences. Presenting data at events like the American Society of Clinical Oncology (ASCO) annual meeting, the American Heart Association Scientific Sessions, or the BIO International Convention reaches thousands of physicians, investors, and payers at once. Conference and publication strategies support each other.

Abstracts submitted to major congresses are often published online before the full peer-reviewed paper. This timing creates an opportunity. If your abstract gets attention at a congress in June, the full journal publication a few months later reaches an audience already familiar with your data. This layered approach builds momentum that single publications cannot achieve on their own.

Preprints on platforms like bioRxiv or medRxiv are now part of the communication process, letting researchers share results before peer review. For some groups, like investors and academic partners, preprints show active progress. For prescribers and payers, peer-reviewed publications remain the standard, so preprints are best used as early updates rather than as final evidence.

Ways conference presentations work alongside your publication plan:

• Poster presentations at specialty congresses: Posters give your team and KOLs the chance to walk through data in real time with physicians who are actively managing patients similar to those in your trial population.
• Late-breaking abstracts: These high-profile presentation slots are reserved for significant new findings and attract disproportionate media and peer attention compared to standard abstract sessions.
• Symposia and satellite sessions: Industry-sponsored satellite sessions at major congresses provide deeper education on disease-state context and therapy mechanisms, complementing the evidence in your publications.
• Post-congress digital reach: Published congress presentations, video summaries, and post-congress press coverage extend the life of your data beyond the event itself.

Beyond enhancing credibility, a well-planned publication strategy is also instrumental in building investor relationships and improving market access.

Scientific publications reach more than just clinical audiences. Institutional investors, venture capital firms, and biotech analysts also follow peer-reviewed data as part of their research on pipeline assets. Publishing in a high-visibility journal at the right time can influence valuation and partnership talks in ways that internal presentations cannot.

When planning your publication strategy, use it to build credibility with prescribers, payers, and investors. Begin by reviewing your upcoming data milestones, target audiences, and possible journal options. Then map out publication and presentation opportunities that align with your business goals. Make your evidence plan a key part of your business strategy, not just an afterthought.

“Biotech companies sometimes underestimate how much payer evidence strategy and publication strategy overlap. By the time you are negotiating with a PBM or a health system formulary committee, the publications you need are already two years old. The time to plan that evidence package is during Phase II, not at launch.” — Strategy Team, Emulent Marketing.

Publication types that directly support market access and investor goals:

• HEOR publications in payer-focused journals: Journals like PharmacoEconomics and Value in Health are read by the exact decision-makers who approve or deny formulary placement.
• Real-world evidence studies: Post-approval data from registries or electronic health record datasets demonstrate how your therapy performs in real-world settings outside controlled trial conditions.
• Systematic reviews and meta-analyses: When your therapy’s data are included in a third-party systematic review, it gains external validation that investor and payer audiences find particularly credible.
• Clinical practice guideline citations: Publications that influence national clinical guidelines, like those from the National Comprehensive Cancer Network (NCCN) or the American Diabetes Association, create durable commercial value that supports prescribing behavior for years.

How Do You Build a Publication Plan That Serves Both Science and Marketing?

A good publication plan balances scientific integrity and marketing goals by matching your evidence to the audiences who need it, not just to journals that will accept it. This requires your medical affairs, market access, and commercial teams to work together when setting publication priorities.

A practical publication plan includes a list of all your data assets, a target journal list organized by audience, a map of KOL authorship, and a timeline linked to regulatory milestones, conference dates, and commercial launch goals. Each publication should have a clear purpose beyond just sharing results.

“The biotech teams we work with that have the most success at launch are the ones that treated their publication plan as a living document from Phase I onward. They know which data assets are coming, who will author them, where they will be published, and how each piece connects to a commercial goal. That level of planning does not happen by accident.” — Strategy Team, Emulent Marketing.

Core components of an integrated publication plan:

• Data asset inventory: A complete list of every study, sub-analysis, and real-world dataset available for publication, along with the clinical and commercial story each one tells.
• Audience-based journal mapping: A tiered list of target journals organized by the audience you need to reach, from specialty clinicians to payer medical directors to academic researchers.
• KOL authorship assignments: A clear plan for which KOLs will lead or co-author each publication, with engagement timelines that allow for genuine scientific contribution.
• Congress abstract calendar: A rolling calendar of abstract submission deadlines for the conferences most relevant to your therapy’s indication, aligned with your data readout schedule.
• Publication gap analysis: A regular review of what your competitors have published and where your own evidence record has openings that could put you at a disadvantage in clinical or payer conversations.

Putting Your Publication Strategy to Work

Scientific publications are one of the few marketing tools in biotech that become more valuable over time. A well-placed, peer-reviewed article can be cited for years, influence clinical guidelines, and shape how physicians talk about your therapy long after launch. Companies that treat publication planning as a business strategy, not just a scientific task, build credibility that competitors cannot easily match.

If your biotech company wants to create a publication strategy that supports clinical adoption, payer access, and investor confidence, the Emulent Marketing Team can help you connect your evidence with the audiences that matter most. Contact us to discuss your biotech marketing strategy.